The U.K.'s cost-effectiveness watchdog has asked Roche ($RHHBY) for more information on Tarceva as a first-line treatment for non-small cell lung cancer. The National Institute for Health and Clinical Excellence noted that a rival drug from AstraZeneca ($AZN), Iressa, is already approved for first-line use, and the Swiss drugmaker hadn't offered enough data on Tarceva as an alternative to that treatment. Report